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Abstract
This study aimed to use 3D printing techniques to create a drug tablet containing two
commonly used active ingredients (metformin and glyburide) for treating diabetes in a single
pill. The hypothesis was that both drugs can be given in doses not available commercially and
that these pills will have appropriate hardness, and extended-release dissolution. I was able to
create 48 tablets that contained evenly dispersed active ingredient powder and met the weight
requirements with consistency between tablets. Unfortunately, we had to substitute the usual
bulk excipient for another because it was incompatible with the metformin and the replacement
(mannitol) may have swelled when exposed to the liquid binder. The tablets produced were tilted
at the top, were softer than normal, broke more easily, and dissolved too quickly. In future
studies, we need to adjust the formulation to enhance hardness and maintain the tablet structure.
Introduction
The 34 million patients with type II diabetes require combination therapy to control their
blood glucose and prevent diseases such as strokes, blindness, and kidney failure. Metformin and
glyburide are antidiabetic prescription drugs made in bulk in factories. Madsen et al. tried to
evaluate the effectiveness of this combination treatment and found inconclusive results in
addition to an increased risk for hypoglycemia with these two drugs.1 Why might that be? For

metformin, available pills come in 500mg or 850mg pills while glyburide is available in 5mg or
10mg pills. If a patient requires 8.5mg of glyburide and 760mg of metformin for the maximal
benefits with minimal adverse events, they are out of luck. Glyburide pills can be cut in half, but
that means the patient must take 1½ tablets to approximate the optimal dose. Metformin pills
cannot be cut, so the prescriber must choose between a higher dose with better benefits but more
adverse events or a lower dose with inadequate benefits but fewer adverse events. Taking 2 ½
pills a day to treat one disease would reduce patients’ willingness to take the drugs over the long
term. When faced with the decision, people often choose a higher dose to avoid the strokes,
blindness, and kidney failure that come with not adequately treating their diabetes. This puts
them at risk of hypoglycemia, as the aforementioned study found, and other adverse events.
What if a patient could receive a tablet, created by a 3D printer right in a pharmacy, that has the
active ingredients from both drugs in one tablet at exactly the dose that patient needs?
Up to this point, different researchers have used 3D printing to achieve goals like creating
a pill with six different drugs that each have unique drug release profiles2, adding a customized
extended release coating around a commercially produced pill3, and making pills with tailored
dosages of an anticoagulant in vivo4. Many techniques have been used, from mixing the active
ingredient into a base powder5, crystallizing the active ingredient and melting it with a laser onto
the building pad2, and dissolving the active ingredient in the liquid binder6. The lab I will be
working in has an Inkjet 3D printer, so active ingredients can be added in either the base powder
or with the liquid binder. Metformin is soluble in water7 but comes in a high dose commercially,
so putting enough metformin in the binder would create an unfavorable dripping pattern.
Glyburide is only soluble in water at a high pH8, which could harm the print head. As such, I
added both drugs into the base powder. I also combined the previously established goals of

having multiple drugs in one pill, using non-commercially available dosages, and having an
extended release dissolution time. My finished product used this technology to improve upon the
specific combination drug therapy for type II diabetes of metformin and a sulfonylurea
(glyburide).
Materials and Methods
UV-Vis spectroscopy was used to create calibration curves (shown in figure 1) for each
of my active ingredients by finding the absorbance readings of their known concentrations. This
allowed me to analyze the concentration of the active ingredients at various steps. Next, I
developed a powder formulation that had a water-soluble excipient (mannitol), an extendedrelease excipient (Hypromellose), a water soluble binder (Kollidon), and my two active
ingredients (metformin and glyburide). My formulation was 72% mannitol, 10% metformin, 9%
Hypromellose, 8% Kollidon, and 1% glyburide. For my liquid binder, I used a 5% Kollidon
solution. To blend the powder, I used a V-blender at 29 rotations per minute for 18 minutes at
40% fill volume. I analyzed the blended powder with UV-Vs spectroscopy to ensure that it was
fully incorporated. Then, I loaded the blended powder mixture and the liquid binder solution into
the HuskyJet 3D printer and printed my tablets.
The HuskyJet is a custom built InkJet 3D printer that creates pharmaceutical tablets. As
shown in figure 2, it works by spraying a layer of powder from the powder reservoir onto the
building platform, dropping the liquid binder from the ink reservoir onto this layer using the print
head, and then rolling the binder into the powder to combine them.
I analyzed my printed tablets for inter-tablet weight variation using an electronic scale,
friability using a friability tester at 25 rotations per minute for 4 minutes, hardness using an Okey
hardness tester, and dissolution behavior using a United States Pharmacopeia (USP) dissolution

apparatus II. I will analyze these tablets again after three months and six months to assess the
long-term stability.
Results
Upon visual inspection, I found that the tablets were slanted instead of straight like a
commercial tablet. This is shown in figure 3. The average deviation of tablet weight was 3.25%.
This passed the United States Pharmacopeia (USP) standards of having less a than 15% average
weight deviation. In the friability tester, the tablets lost 27% of their weight. This failed the USP
standard of having less than 1% weight loss. I found that the average hardness was 1.1 kg/force
from the Okey hardness tester. Most tablets tend to be between 4 and 8 kg/force, and I was
aiming for the high end of this range, since it was meant to be extended release. The dissolution
time was between 1 and 3 hours. The dissolution behavior is shown in figure 4. The peak in the
data is a misreading because any reading over an absorbance of 2 is inaccurate. When the
absorbance reading declines, that means the tablet has fully dissolved.
Discussion and Conclusion
The inter-tablet weight variation passing USP standards means that the HuskyJet 3D
printer successfully created tablets of similar size. However, the tablets were not the correct
shape and were too soft. Since the problem is not the 3D printer, I believe the problem is the
formulation. I think the tablets were slanted because when the liquid binder was jetted onto the
powder, the powder absorbed it and expanded. So, when the roller reached the powder, it shifted
the tablets, making them slant instead of compress. Because of this problem, we had to increase
the layer thickness, which means the liquid binder was not able to seep through the entire layer,
and it didn’t bind as well. This made my tablets soft. To solve this problem, I will change the
formulation. My lab has never tried to use mannitol as the main excipient before. Previous

experiments have determined that lactose monohydrate is the best water soluble bulk excipient
for 3D printing. However, lactose monohydrate undergoes the Maillard reaction when in
presence of metformin, which could inactivate it. That is why I substituted lactose monohydrate
for mannitol. Therefore, I will have to experiment with mannitol in the formulation, like
changing the percentage of mannitol or adding another bulk ingredient that will not swell. In
addition to changing the formulation, I will also use a film coater to put a coating on the tablets
that could improve their friability, hardness, and dissolution behavior.
If I succeed in making this tablet, there could be further studies of the 3D printed drugs in
vitro. The next step will be to assure that the tablets, and the active ingredients inside them, are
stable for 90 days, the time a person would use a personalized tablet for. After this step, there is
work in vivo to show whether this process works the same inside a living being. Later, there
could be large clinical studies of these 3D printed tablets with exact dosages used to treat
diabetes in comparison to taking separate commercial metformin and glyburide. Since type II
diabetes is a long-term disease, an easier treatment can make a big change for people living with
it. Furthermore, if I can make a single pill that is more effective for treating diabetes, then
eventually, custom pills can be made to treat multiple diseases. Pill burden decreases quality of
life, particularly for the elderly population, so consolidating multiple medications into a single
dose can improve the lives of countless patients. 3D printing technology is revolutionary for
personalized medicine. Eventually, there could be a 3D printer in every pharmacy to make a
particular pill for each person who needs one.
In conclusion, we were able to create tablets with the appropriate amount of active
ingredients and with consistent weight. However, we need to further refine our formulation to
overcome our excessively soft tablets in the next experiment.
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Figure 1: UV-Vis spectroscopy calibration curves of active ingredients
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Figure 2: Process of 3D printing drugs

Figure 3: 3D printed tablets
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Figure 4: Dissolution behavior of metformin
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